DexCom, Inc. (NASDAQ:DXCM) a medical device firm, is expected to report third quarter earnings results, after market close, on Tuesday 27th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.64 per share.
Looking ahead, the full year income are expected at $ 2.74 per share on the revenues of $ 1869.87 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,850.00 million ~ $ 1,850.00 million
Click Here For More Historical Outlooks Of DexCom, Inc.
Previous Quarter Performance
DexCom, Inc. outlined income for the second quarter of $ 0.79 per share, from the revenue of $ 451.80 million. The quarterly earnings swell 887.50 percent while revenues expanded 34.30 percent compared with the same quarter last year.
Street analysts expected DexCom, Inc. to report income of $ 0.35 per share on revenue of $ 415.74 million for the second quarter. The bottom line results beat street analysts by $ 0.44 or 125.71 percent, at the same time, top line results outshined analysts by $ 36.06 million or 8.67 percent.
Stock Performance
Shares of DexCom, Inc. traded up $ 15.21 or 3.84 percent on Friday, reaching $ 411.00 with volume of 535.00 thousand shares. DexCom, Inc. has traded high as $ 411.21 and has cracked $ 396.97 on the downward trend
According to the previous trading day, closing price of $ 411.00, representing a 168.30 % increase from the 52 week low of $ 147.52 and a 13.25 % decrease over the 52 week high of $ 456.23.
The company has a market capital of $ 39.35 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 2nd October 2020, downgraded by Wells Fargo & Co to Underweight from Equal-Weight rating, with $ 350.00 target price.
Conference Call
DexCom, Inc. will be hosting a conference call at 4:30 PM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.dexcom.com
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patients mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
